[Clinical and bacteriologic effectiveness of ceftazidime in infections with gram-positive pathogens].
From June 1984 to March 1985 an open, multicenter study was carried out to evaluate the efficacy and safety of ceftazidime in the empirical treatment of severe nosocomial infections. 3799 patients treated in 513 clinical care units were included and 3477 were evaluable. The majority was older than 60 years; most patients showed severe underlying diseases and were in a critical condition. The clinical and bacteriological results with various monoinfections due to gram-positive bacteria are presented. Staphylococcus aureus, Streptococcus pneumoniae and other streptococci were the most frequently isolated organisms. 600 patients with infections due to staphylococci were evaluated separately. The clinical success rate with ceftazidime in S. aureus monoinfections was 90.9%, and the bacteriological success rate was 74.9%.
Tolxdorff-Neutzling
R
R
Cascan GmbH & Co. KG, Wiesbaden.
Klages
G
G
Danner
H
H
D001424:Bacterial Infections / Q000188:drug therapy*; D002442:Ceftazidime / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D018805:Sepsis / Q000188:drug therapy
D002442:Ceftazidime
Klinische und bakteriologische Wirksamkeit von Ceftazidim bei Infektionen mit grampositiven Erregern.